2 results
Approved WMOCompleted
To make laquinimod 0.6 mg available for all subjects who completed the placebo-controlled MS-LAQ-301 study according to the protocol and to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in…
Approved WMOCompleted
To determine the safety, tolerability and pharmacokinetics of an 18-hour i.v. infusion of CLR325 in stable heart failure patients.